INTRATUMORAL ADAPTIVE IMMUNOSUPPRESSION AND TYPE 17 IMMUNITY IN MISMATCH REPAIR PROFICIENT COLORECTAL TUMORS

PURPOSE: Approximately 10% of mismatch repair proficient (MMRp) colorectal cancer (CRC) patients showed clinical benefit to anti-PD-1 monotherapy (). We sought to identify biomarkers that delineate patients with immunoreactive CRC and to explore new combinatorial immunotherapy strategies that can im...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Cancer Res
Asıl Yazarlar: Llosa, Nicolas J., Luber, Brandon, Tam, Ada J., Smith, Kellie N., Siegel, Nicholas, Awan, Anas H., Fan, Hongni, Oke, Teniola, Zhang, JiaJia, Domingue, Jada, Engle, Elizabeth L., Roberts, Charles A., Bartlett, Bjarne R., Aulakh, Laveet K., Thompson, Elizabeth D., Taube, Janis M., Durham, Jennifer N., Sears, Cynthia L, Le, Dung T, Diaz, Luis A., Pardoll, Drew M., Wang, Hao, Anders, Robert A., Housseau, Franck
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2019
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6726531/
https://ncbi.nlm.nih.gov/pubmed/31061070
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-0114
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller